Monday, 16 Sep 2019

You are here

Number of Prior DMARDs Portends Poorer Outcomes

Detailed analysis of two clinical trials in rheumatoid arthritis (RA) has shown that clinical responses decrease as the disease duration and number of prior disease-modifying antirheumatic drugs (DMARDs) increase.

The associations between disease duration and number of prior DMARDs and response to therapy were assessed using data from two randomised controlled trials in patients with established RA (mean duration, 11 years) receiving adalimumab+methotrexate.

Clinical efficacy responses were assessed at week 24 using standard disease activity outcomes.

Both trials demonstrated that a greater number of prior DMARDs and longer RA duration were associated with lower ACR response rates at week 24.

In one trial of 207 RA patients showed when comparing a many to few prior DMARDs (>2 vs 0–1) there was smaller improvements by week 24 in:

  • DAS28(CRP) (–1.8 vs –2.2)
  • SDAI (–22.1 vs –26.9)
  • HAQ-DI (–0.43 vs –0.64)\.

When comparing disease duration (>10 years versus <1 year) higher HAQ-DI scores (1.1 vs 0.7) were seen at week 24, but results on DAS28(CRP) and SDAI were mixed.

Number of prior DMARDs, moreso than disease duration, appears to identify refractory RA patients who may not respond as well to future treatment interventions.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Two vs. Four Weeks of Antibiotic Therapy in Septic Arthritis

A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.

This Swiss study was a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults. 

Bimekizumab Add-on Therapy in Rheumatoid Arthritis

Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis patients not adequately controlled by certolizumab pegol resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA.

74 Percent of Rheumatoid Arthritis Patients Dissatisfied with Treatment

CreakyJoints has completed a 258 patient survey showing that nearly three-fourths of people with rheumatoid arthritis (RA) have expressed dissatisfaction with their treatments, including conventional (csDMARDs) and biologic Disease Modifying Antirheumatic Drugs (bDMARDs).

RA Women are Less Likely to Breastfeed

A large pregnancy registry has published their results showing rheumatoid arthritis (RA) patients who become pregnant are less likely to breastfeed compared to non-RA women from the general population, with many women stopping breastfeeding so that they could start medication, even though many of these meds are safe to use during lactation.

Respiratory Risks Not Increased in RA Patients with COPD

An insurance claims based study of RA patients with COPD shows that biologics do not have an increased rate of respiratory events compared to those on conventional DMARDs. A real world cohort of RA patients with COPD was drawn from US-based MarketScan databases. Patients on biologic DMARDs and/or targeted synthetic DMARDs (tsDMARDs) were propensity matched to those on conventional synthetic DMARDs (csDMARDs).